Advertisement

H3 Biomedicine Inc., a personalized cancer drug discovery company launched earlier this year,  is opening its new headquarters and 24,000 square feet of laboratory space in Cambridge this afternoon. The privately held company has $200 million in research funding from Japanese pharmaceutical maker Eisai.

SOURCE

Advertisement
Advertisement